T Cerny
Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non-small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices
Ess S, Herrmann C, Frick H, Krapf M, Cerny T, Jochum W, Früh M. Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non-small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices. Eur J Cancer Care (Engl) 2017
30.05.2017Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non-small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices
30.05.2017Eur J Cancer Care (Engl) 2017
Ess S M, Herrmann C, Frick H, Krapf M, Cerny T, Jochum Wolfram, Früh Martin
Fear, Pain, Denial, and Spiritual Experiences in Dying Processes
Renz M, Reichmuth O, Bueche D, Traichel B, Mao M, Cerny T, Strasser F. Fear, Pain, Denial, and Spiritual Experiences in Dying Processes. Am J Hosp Palliat Care 2017:1049909117725271.
01.01.2017Fear, Pain, Denial, and Spiritual Experiences in Dying Processes
01.01.2017Am J Hosp Palliat Care 2017:1049909117725271
Renz M, Reichmuth O, Bueche D, Traichel B, Mao M Schuett, Cerny T, Strasser Florian
Rituximab: active treatment of central nervous system involvement by non-Hodgkin's lymphoma?
Ruhstaller T, Amsler U, Cerny T. Rituximab: active treatment of central nervous system involvement by non-Hodgkin's lymphoma?. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000; 11:374-5.
01.03.2000Rituximab: active treatment of central nervous system involvement by non-Hodgkin's lymphoma?
01.03.2000Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000; 11:374-5
Ruhstaller Thomas, Amsler U, Cerny T
Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK)
Joss R, Stahel R, Martinelli G, Cerny T, Thürlimann B, Leyvraz S, Bacchi M, Hürny C, Alberto P, Ludwig C. Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995; 6:41-8.
01.01.1995Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK)
01.01.1995Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995; 6:41-8
Joss R A, Stahel R, Martinelli G, Cerny T, Thürlimann Beat, Leyvraz S, Bacchi M, Hürny C, Alberto P, Ludwig C